阿帕替尼联合经肝动脉化疗栓塞术治疗肝细胞癌的研究进展

朱泽民; 赵志坚; 唐才喜

doi:10.3969/j.issn.1001-5256.2020.10.036

阿帕替尼联合经肝动脉化疗栓塞术治疗肝细胞癌的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.10.036

中南大学湘雅医学院附属株洲医院肝胆胰脾外科

基金项目:

湖南省科技计划项目经费资助(2016SK4006)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 563
- HTML全文浏览量: 21
- PDF下载量: 84
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-17
- 出版日期: 2020-10-20

Research advances in apatinib combined with transcatheter arterial embolization in the treatment of hepatocellular carcinoma

Department of Hepatobiliary and Pancreatosplenic Surgery,Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University

Research funding:

摘要

摘要: 肝细胞癌是一种威胁全人类健康的常见恶性肿瘤,其发病率和病死率不断上升。大多数肝细胞癌患者确诊时已为中晚期,无法接受潜在的治疗性手术。经肝动脉化疗栓塞术(TACE)和抗血管生成药物阿帕替尼是治疗肝细胞癌的两种姑息治疗方法。目前,阿帕替尼联合TACE的应用在临床中治疗肝细胞癌仍然是一种新的治疗方法,有关其临床疗效和安全性目前尚存在争议,需进一步研究。综述了阿帕替尼联合TACE治疗肝细胞癌的研究进展。
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 阿帕替尼
Abstract: Hepatocellular carcinoma( HCC) is a common malignant tumor that threatens the health of all mankind,and its incidence and mortality rates keep increasing in recent years. Most patients are in the advanced stage at the time of confirmed diagnosis and are unable to undergo potential therapeutic surgery. Transcatheter arterial chemoembolization( TACE) and the anti-angiogenic drug apatinib are two palliative treatments for HCC. At present,apatinib combined with TACE is still a new treatment method for HCC in clinical practice,and there are still controversies over its efficacy and safety,which needs further studies. This article reviews the research advances in apatinib combined with TACE in the treatment of HCC.
- carcinoma,hepatocellar /
- chemoembolization,therapeutic /
- apatinib

HTML全文

参考文献(34)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] MEYER T,PALMER DH,CHENG AL,et al. mRECIST to predict survival in advanced hepatocellular carcinoma:Analysis of two randomised phase II trials comparing nintedanib vs sorafenib[J]. Liver Int,2017,37(7):1047-1055.

[3] ZHANG J,LI H,GAO D,et al. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE[J]. Cancer Biol Ther,2018,19(6):475-483.

[4] LIU C,XING W,SI T,et al. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus:A retrospective study[J]. Oncotarget,2017,8(59):100734-100745.

[5] FLYNN MJ,SAYED AA,SHARMA R,et al. Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma[J]. Hepatology,2019,69(5):2258-2270.

[6] PECK-RADOSAVLJEVIC M,KUDO M,RAOUL JL,et al.Outcomes of patients(PTS)with hepatocellular carcinoma(HCC)treated with transarterial chemoembolization(TACE):Global OPTIMIS final analysis[J]. J Clin Oncol,2018,36(15_suppl):4018.

[7] QIU Z,SHEN L,CHEN S,et al. Efficacy of apatinib in transcatheter arterial chemoembolization(TACE)refractory intermediate and advanced-stage hepatocellular carcinoma:A propensity score matching analysis[J]. Cancer Manag Res,2019,11:9321-9330.

[8] CHEN S,YU W,ZHANG K,et al. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma[J]. BMC Cancer,2018,18(1):1131.

[9] LIU J,XIE S,DUAN X,et al. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma[J].Cancer Chemother Pharmacol,2020,85(1):69-76.

[10] YANG Z,CHEN G,CUI Y,et al. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma:A retrospective study[J]. Cancer Biol Ther,2019,20(3):321-327.

[11] LIU J,XU J,ZHANG W,et al. Safety and efficacy of drugeluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma[J]. Acad Radiol,2020,27(5):704-709.

[12] PADIA SA. Is idarubicin the future of TACE?[J]. Radiology,2019,291(3):809-810.

[13] LIU X,WANG Z,CHEN Z,et al. Efficacy and safety of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion in hepatocellular carcinoma:A systematic review and meta-analysis[J]. Oncol Res,2018,26(2):231-239.

[14] WANG B,XU H,GAO ZQ,et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Acta Radiol,2008,49(5):523-529.

[15] PAN Z,ZHUANG J,JI C,et al. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression[J]. Oncol Lett,2018,15(4):4821-4826.

[16] KONG Y,SUN L,HOU Z,et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma[J]. Oncotarget,2017,8(62):105596-105605.

[17] SCOTT LJ. Apatinib:A review in advanced gastric cancer and other advanced cancers[J]. Drugs,2018,78(7):747-758.

[18] ALITALO K,CARMELIET P. Molecular mechanisms of lymphangiogenesis in health and disease[J]. Cancer Cell,2002,1(3):219-227.

[19] YANG C,QIN S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma[J]. Cancer Med,2018,7(9):4570-4583.

[20] TIAN S,QUAN H,XIE C,et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Sci,2011,102(7):1374-1380.

[21] QIN SK,BAI YX,OUYANG XN,et al. Apatinib for patients with advanced hepatocellular carcinoma:A randomised,open label,multicentre,phaseⅡclinical trial[J]. Chin Clin Oncol,2017,22(12):1057-1065.(in Chinese)秦叔逵，白玉贤，欧阳学农，等．阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J]．临床肿瘤学杂志，2017,22(12):1057-1065.

[22] ZHAO J,LEI J,YU J,et al. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma[J]. Invest New Drugs,2020,38(2):500-506.

[23] ZHANG H,SUN J,JU W,et al. Apatinib suppresses breast cancer cells proliferation and invasion via angiomotin inhibition[J]. Am J Transl Res,2019,11(7):4460-4469.

[24] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292.

[25] HE F,CHEN XD,LIN ZW,et al. Analysis of the effect of transcatheter arterial chemoembolization(TACE)combined with apatinib in patients with advanced hepatocellular carcinoma[J]. Anti-Tumor Pharm,2018,8(3):383-386.(in Chinese)何凡，陈旭东，林振文，等．中晚期肝癌患者应用经导管肝动脉化疗栓塞(TACE)联合阿帕替尼治疗的效果分析[J]．肿瘤药学，2018,8(3):383-386.

[26] ZHU Y,FENG B,MEI L,et al. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma[J]. J BUON,2019,24(2):608-614.

[27] LU W,JIN XL,YANG C,et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma:A single-center randomized controlled trial[J]. Cancer Biol Ther,2017,18(6):433-438.

[28] CHEN L,KE Z,XIONG F,et al. Platelet-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization plus apatinib in the treatment of advanced hepatocellular carcinoma[J]. Anticancer Drugs,2020.[Online ahead of print]

[29] YAO Q. Experimental study on the effect of inhibiting tumor angiogenesis after embolization in the treatment of liver cancer treated with Apatinib loaded iodized oil[D]. Wuhan:Huazhong University of Science and Technology,2017.(in Chinese)姚琦．碘化油载阿帕替尼经肝动脉栓塞治疗兔VX2肝癌及抑制栓塞后肝癌血管新生的实验研究[D]．武汉:华中科技大学，2017.

[30] LU Y,JIANG YN,WAN C,et al. Curative effect of apatinib combined with TACE for advanced hepatocellular carcinoma[J]. J Intervent Radiol,2019,28(2):162-165.(in Chinese)陆阳，姜永能，万程，等．阿帕替尼联合TACE治疗中晚期肝细胞癌的疗效研究[J]．介入放射学杂志，2019,28(2):162-165.

[31] YU JY,GUO HL,TIAN XY,et al. PhaseⅡtrial of apatinib mesylate tablets combined with transarterial chemoembolization for advanced hepatocelluar carcinoma[J]. J Southeast Univ(Med Sci Edi),2018,37(1):74-77.(in Chinese)于俊岩，郭红亮，田向阳，等．甲磺酸阿帕替尼联合经导管动脉化疗栓塞治疗肝细胞肝癌的Ⅱ期临床试验[J]．东南大学学报(医学版)，2018,37(1):74-77.

[32] KOU P,ZHANG Y,SHAO W,et al. Significant efficacy and well safety of apatinib in an advanced liver cancer patient:A case report and literature review[J]. Oncotarget,2017,8(12):20510-20515.

[33] XIE YJ,SHEN LR,CHEN L,et al. Three cases of adverse drug reactions induced by apatinib and literature review[J].Chin J New Drugs,2019,28(8):1021-1024.(in Chinese)谢燕瑾，沈丽蓉，陈玲，等．阿帕替尼不良反应3例及文献回顾[J]．中国新药杂志，2019,28(8):1021-1024.

[34] WU J,YIN F,LUO GH,et al. Clinical effect and safety of transarterial chemoembolization combined with apatinib in treatment of advanced primary liver cancer[J]. J Clin Hepatol,2018,34(4):775-778.(in Chinese)武健，尹芳，罗贯虹，等．经肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌的效果及安全性分析[J]．临床肝胆病杂志，2018,34(4):775-778.

施引文献

资源附件(0)

访问统计